Literature DB >> 25000353

Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease.

Ingrid J M Han-Geurts1, Vivian C Hendrix, Ivo de Blaauw, Marc H W A Wijnen, Ernest L W van Heurn.   

Abstract

OBJECTIVES: A nonrelaxing internal anal sphincter is present in a relatively large proportion of children with surgically treated Hirschsprung disease (HD) and can cause obstructive gastrointestinal symptoms. The short- and long-term outcome and adverse effects of intrasphincteric botulinum toxin (Botox) injections in children with obstruction after surgically treated HD are evaluated.
METHODS: The outcome of children with surgically treated HD treated with intrasphincteric Botox injections for obstructive symptoms was analyzed with a retrospective chart review between 2002 and 2013 in the University Medical Centers of Maastricht and Nijmegen.
RESULTS: A total of 33 patients were included. The median time of follow-up was 7.3 years (range 1-24). A median of 2 (range 1-5) injections were given. Initial improvement was achieved in 76%, with a median duration of 4.1 months (range 1.7-58.8). Proportion of children hospitalized for enterocolitis decreased after treatment from 19 to 7. A good long-term response was found in 49%. Two children experienced complications: transient pelvic muscle paresis with impairment of walking. In both children symptoms resolved within 4 months without treatment.
CONCLUSIONS: Intrasphincteric Botox injections in surgically treated HD are an effective long-term therapy in approximately half of our patients with obstructive symptoms. The possibility of adverse effects should be noticed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25000353     DOI: 10.1097/MPG.0000000000000483

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  8 in total

Review 1.  The Role of Botox in Colorectal Disorders.

Authors:  Dan Carter; Ram Dickman
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

2.  Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children.

Authors:  Ricardo A Arbizu; Leonel Rodriguez
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

3.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

4.  Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease.

Authors:  Tomas Wester; Anna Löf Granström
Journal:  Pediatr Surg Int       Date:  2015-01-24       Impact factor: 1.827

Review 5.  Hirschsprung Disease beyond Infancy.

Authors:  Casey M Calkins
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

Review 6.  Treatment of gastrointestinal sphincters spasms with botulinum toxin A.

Authors:  Giuseppe Brisinda; Nicola Sivestrini; Giuseppe Bianco; Giorgio Maria
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

Review 7.  ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease.

Authors:  Kristiina Kyrklund; Cornelius E J Sloots; Ivo de Blaauw; Kristin Bjørnland; Udo Rolle; Duccio Cavalieri; Paola Francalanci; Fabio Fusaro; Annette Lemli; Nicole Schwarzer; Francesco Fascetti-Leon; Nikhil Thapar; Lars Søndergaard Johansen; Dominique Berrebi; Jean-Pierre Hugot; Célia Crétolle; Alice S Brooks; Robert M Hofstra; Tomas Wester; Mikko P Pakarinen
Journal:  Orphanet J Rare Dis       Date:  2020-06-25       Impact factor: 4.123

8.  Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease.

Authors:  Joong Kee Youn; Ji-Won Han; Chaeyoun Oh; So-Young Kim; Sung-Eun Jung; Hyun-Young Kim
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.